Navigation Links
Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
Date:7/12/2010

PRINCETON, N.J., July 12 /PRNewswire/ -- Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan.  Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs). The DRx AFC Medirepair® website can be found at: http://www.drx-web.com/aa/prod_afc.htm .

"We're excited to launch Arazine™ in the Japanese market providing a completely new and effective product for treating skin inflammation," said Signum president, Maxwell Stock.  "The commercialization of Arazine™ is a significant milestone for Signum and validates our underlying business model."

Arazine™ is a Signal Transduction Modulator (STM) with anti-inflammatory properties, which has been developed for topical skin treatment.  STMs block inflammation and neutrophil infiltration in chronic redness, acne, skin irritation, and other skin conditions by modulating G-protein signal transduction pathways.  They also act as antioxidants to neutralize free radicals and prevent UV damage, cellular degeneration and production of chemicals that cause further damage.  Arazine™ is closely followed by Signum's pipeline of compounds including SIG990 which is being developed for rosacea and other inflammatory skin conditions.

Signum and Rohto announced their strategic alliance to develop and commercialize skincare products in Japan during 2008.  Rohto gained semi-exclusive rights to develop and sell products in Japan that contain Signum's anti-inflammatory compound Arazine™.  

About Signum Biosciences.

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from its Signal Transduction Modulation (STM) platform to modulate signal transduction imbalances. Through research on protein networks that control biological systems, Signum is developing therapeutic candidates for Alzheimer's, Parkinson's, diabetes, asthma and certain skin conditions. Signum's STM technology provides many opportunities for the development of novel consumer products and pharmaceutical candidates.

For more information please visit the Signum website: www.signumbiosciences.com

About Rohto Pharmaceutical Co., Ltd.

Rohto Pharmaceutical Co., Ltd. is among the largest manufacturers and marketers of pharmaceutical and other healthcare products in Japan. Founded in 1899, the company is based in Osaka, Japan. Production sites include facilities in the U.S., Europe, Latin America, China and Southeast Asia with product distribution to over 150 countries including all of Asia, the Americas and Europe. In 1988 the company acquired management rights to prominent U.S. manufacturer, The Mentholatum Company, Inc. Corporate sales revenue in the latest fiscal year exceeded US$ 1 Billion. The Chairman and CEO is Mr. Kunio Yamada.

For more information please visit the Rohto website: www.rohto.co.jp/global


'/>"/>
SOURCE Signum Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
2. Ampio Pharmaceuticals to Acquire DMI Biosciences, Inc.
3. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
4. Neurocrine Biosciences, Inc. Prices Common Stock Offering
5. Hollis-Eden Announces Name Change to Harbor BioSciences, Inc. and Ticker Symbol Change to HRBR
6. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
7. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
8. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
11. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... , May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of ... is based on extensive data analysis from GHI,s hospitals ... hospitals database for the region. The GHI database covers 86% ... offering more than 130 data points for each institution in ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/6/2017)... Texas , May 5, 2017   Provista , ... with more than 200,000 customers, today announced Jim Cunniff ... a wealth of executive and business experience to Provista, including ... compounding pharmacy in California . He assumed ... "Jim is a great fit for Provista," says ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® or ... a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance of ... Dr. Bedich offers a variety of cosmetic dentistry services at his practice that are ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... reproductive tract in which the endometrial lining of the uterus spreads into ... pain. Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding ...
(Date:5/24/2017)... NY (PRWEB) , ... May 24, 2017 , ... ... the practice is offering holistic pediatric dentistry options for its patients on Long ... of the patient’s entire physical well being, and is one of the biggest ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... ... May 23, 2017 , ... Allegheny Health Network ... The Alexis Joy D’Achille Center for Women’s Behavioral Health at West Penn Hospital ... western Pennsylvania for women suffering from pregnancy-related depression. Construction of the Center is ...
Breaking Medicine News(10 mins):